Trials / Recruiting
RecruitingNCT06424665
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FZ-AD005 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FZ-AD005 | Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study. |
Timeline
- Start date
- 2024-07-03
- Primary completion
- 2026-08-01
- Completion
- 2027-12-01
- First posted
- 2024-05-22
- Last updated
- 2026-03-04
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06424665. Inclusion in this directory is not an endorsement.